Spots Global Cancer Trial Database for aml
Every month we try and update this database with for aml cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) | NCT00486265 | Acute Myelogeno... | AZD4877 | 18 Years - | AstraZeneca | |
| Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients | NCT00952588 | Acute Myeloid L... | AZD1152 LDAC | 60 Years - | AstraZeneca | |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| TL-895 and KRT-232 Study in Acute Myeloid Leukemia | NCT04669067 | Acute Myeloid L... | TL-895 KRT-232 | 18 Years - | Telios Pharma, Inc. | |
| A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT01305499 | Acute Myeloid L... | Entinostat days... 5AC Entinostat days... | 60 Years - | Case Comprehensive Cancer Center | |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) | NCT02243124 | Myelodysplastic... | cenersen Dexamethasone | 18 Years - 95 Years | Eleos, Inc. | |
| Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | NCT01758367 | Recurrent Adult... | Deciatbine(DAC) | 18 Years - 60 Years | Chinese PLA General Hospital | |
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | NCT00136422 | Acute Myelogeno... Myelodysplasia | autologous tumo... | 18 Years - | Dana-Farber Cancer Institute | |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | NCT03217838 | Acute Myeloid L... | AZD2811 Azacitidine Venetoclax | 18 Years - 130 Years | AstraZeneca | |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | NCT04217278 | Acute Myeloid L... High-risk Myelo... | Vyxeos Fludarabine Busulphan Thiotepa Cytarabine | 18 Years - | University of Birmingham | |
| Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome | NCT01311258 | Acute Myeloid L... Myelodysplastic... | 18 Years - | University of Rochester | ||
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD | NCT03622541 | FLT3-ITD Mutati... AML | Sorafenib 200mg | 18 Years - | The University of Hong Kong | |
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | NCT04079738 | AML AML, Adult | TAK-659 Ixazomib | 18 Years - | Big Ten Cancer Research Consortium | |
| The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | NCT05756322 | Relapsed or Res... | LBS-007 | 18 Years - 120 Years | Lin BioScience, Inc | |
| Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial | NCT02160600 | Renal Cell Carc... Renal Cysts Transitional Ce... AML | Standard multip... split bolus Dua... | 18 Years - | All India Institute of Medical Sciences, New Delhi | |
| Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | NCT00720850 | Myelodysplastic... Acute Myelogeno... | lenalidomide | 18 Years - | Technische Universität Dresden | |
| Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations | NCT02272478 | Acute Myeloid L... Myelodysplastic... | Arm A Mylotarg ... Arm B Vosaroxin... Arm D Small mol... Arm C DA V FLAG... Arm E CPX-351 (... Arm F DA V IDAC | 60 Years - | Cardiff University | |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant | NCT03739502 | AML NHL Hodgkin Disease All Myelodysplastic... | Hyperbaric oxyg... | 18 Years - 70 Years | University of Rochester | |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | NCT00488592 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1:126-134 PR1:169-177 Pep... GM-CSF (Sargram... Montanide adjuv... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | NCT00357565 | Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo... | filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ... | - 3 Years | Masonic Cancer Center, University of Minnesota | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | NCT03417154 | Acute Myeloid L... Higher Risk Mye... | Nivolumab Low dose Cyclop... Low dose Cyclop... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | NCT05520567 | Acute Myeloid L... FLT3-mutated Ac... | Gilteritinib Venetoclax Azacitidine | 18 Years - | Astellas Pharma Inc | |
| Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00948064 | Leukemia | Vorinostat Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | NCT01261312 | MDS CMML AML | SGI-110 SGI-110 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT00778375 | Acute Myeloid L... Myelodysplastic... | Clofarabine Cytarabine Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| CD34 Selection Using the Automated CliniMACS Prodigy | NCT06047886 | AML ALL Lymphoid Malign... Myelodysplastic... CML Primary Myelofi... | Infusion of CD3... | 4 Weeks - 75 Years | University of Alabama at Birmingham | |
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | NCT00542971 | AML Acute Myeloid L... Myelodysplastic... | Idarubicin Sorafenib Ara-C | 15 Years - 60 Years | M.D. Anderson Cancer Center | |
| Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | NCT00038805 | Leukemia | Mylotarg | 55 Years - 75 Years | M.D. Anderson Cancer Center | |
| Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | NCT00074750 | Acute Myelogeno... Chronic Myelomo... | DTGM | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | NCT05155709 | Acute Myeloid L... | siremadlin venetoclax azacitidine | 18 Years - 99 Years | Novartis | |
| A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00136461 | Acute Myelogeno... Myelodysplastic... | All-trans retin... Bryostatin 1 | 18 Years - | Dana-Farber Cancer Institute | |
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | NCT02016729 | Advanced Malign... Cancer Oncology Oncology Patien... Acute Myeloid L... | AMG 232 Trametinib | 18 Years - | Kartos Therapeutics, Inc. | |
| Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | NCT00689000 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CHR-2797 (tosed... | 18 Years - | Chroma Therapeutics | |
| Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | NCT02203773 | Acute Myelogeno... Myelogenous Leu... Treatment Naive... | Posaconazole ABT-199 Decitabine Azacitidine | 60 Years - | AbbVie | |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | NCT00089596 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Non-Hodgkin Lym... Chronic Myeloge... | Expansion of um... | 12 Years - 60 Years | ViaCell | |
| Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | NCT03150004 | Acute Myeloid L... Myelodysplastic... | Cladribine, Cyt... Cladribine and ... | 18 Years - | Medical College of Wisconsin | |
| Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia | NCT04571645 | Acute Myeloid L... | Dociparstat Control | 18 Years - | Chimerix | |
| Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | NCT00943943 | Acute Myelogeno... Leukemia | G-CSF Plerixafor Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World | NCT04337138 | Leukemia, Myelo... | Gemtuzumab Ozog... | 18 Years - | Pfizer | |
| Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia | NCT00126893 | Myeloid Leukemi... | CC-401 | 18 Years - | Celgene | |
| Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients | NCT00386373 | Leukemia | Imatinib Mesyla... | 16 Years - | M.D. Anderson Cancer Center | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | NCT03106428 | Acute Myeloid L... Multiple Myelom... Diffuse Large B... | MEDI7247 | 18 Years - 100 Years | MedImmune LLC | |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) | NCT02610062 | Acute Myeloid L... | AGS67E | 18 Years - | Astellas Pharma Inc | |
| Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | NCT02795520 | AML Advanced MDS ALL Advanced CML Advanced MPNs | OTS167IV | 18 Years - | OncoTherapy Science, Inc. | |
| A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure | NCT05875649 | AML | CLAG | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study | NCT00715637 | Secondary Acute... | Daunorubicin an... Amonafide and C... | 18 Years - | Antisoma Research | |
| Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML | NCT02427919 | Leukemia, Myelo... | G-CSF | 17 Years - 64 Years | Seoul St. Mary's Hospital | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | NCT00890929 | Acute Myeloid L... Adult Acute Mye... | Lenalidomide Azacitidine | 60 Years - | Stanford University | |
| Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) | NCT00398983 | Acute Myelogeno... | Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | NCT01242774 | Acute Myeloid L... | Panobinostat | 18 Years - 65 Years | Novartis | |
| FLYSYN in MRD Positive AML | NCT02789254 | Acute Myeloid L... | FLYSYN | 18 Years - | Synimmune GmbH | |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | NCT00405743 | Hematologic Mal... AML | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Study of AMV564 in Patients With AML | NCT03144245 | Acute Myeloid L... | AMV564 AMV564 in combi... | 18 Years - | Amphivena Therapeutics, Inc. | |
| A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | NCT02859948 | Acute Myeloid L... | SKLB1028 | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes | NCT05057299 | Acute Myeloid L... | retrospective d... | 18 Years - | King Hussein Cancer Center | |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | NCT00013533 | Hodgkin Lymphom... Lymphocytic Leu... Mixed Cell Leuk... Myelodysplastic... Non Hodgkin's L... CML ALL AML Lymphoma | Stem cell trans... | 4 Years - 20 Years | National Institutes of Health Clinical Center (CC) | |
| (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive | NCT02039726 | AML | Quizartinib Salvage Chemoth... | 18 Years - | Daiichi Sankyo | |
| Allogeneic Transplant in HIV Patients (BMT CTN 0903) | NCT01410344 | Leukemia Lymphoma HIV | Fludarabine and... Fludarabine and... Busulfan and Fl... Cyclophosphamid... | 15 Years - | Medical College of Wisconsin | |
| PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | NCT03927261 | Acute Myeloid L... Myelodysplastic... | PRGN-3006 T Cel... | 18 Years - | Precigen, Inc | |
| Molecular Epidemiology of Acute Myelogenous Leukemia | NCT00502983 | Leukemia | Interview | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | NCT01463046 | Acute Myeloid L... Advanced Myelod... | Panobinostat Cytarabine Daunorubicin | 18 Years - | University of California, San Francisco | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Study of Maintenance With Azacitidine in MDS Patients | NCT00446303 | Leukemia, Myelo... Myelodysplastic... | Azacitidine | 18 Years - 85 Years | Groupe Francophone des Myelodysplasies | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
